{"entity":{"id":"nct07232849","kind":"trial","name":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of HRS-4508 tablet in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07232849 by Jiangsu HengRui Medicine Co., Ltd., with 100 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12. Interventions recorded: HRS-4508 tablet.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07232849","url":"https://clinicaltrials.gov/study/NCT07232849"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07232849","phase":"2","setting":"Study on Efficacy and Safety of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":100,"outcomes":[]},"route":"/trials/nct07232849/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}